The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Non-Alcoholic Steatohepatitis Treatment Market’s Market Value Anticipated To Evolve From 2026 To 2030?
The non-alcoholic steatohepatitis treatment market size has expanded considerably in recent years. It is projected to increase from $3.57 billion in 2025 to $4.98 billion in 2026, at a compound annual growth rate (CAGR) of 39.6%. The market’s historical growth can be attributed to the rising prevalence of obesity, an increasing incidence of type 2 diabetes, high consumption of processed foods, a lack of awareness about liver health, and limited treatment options for early-stage nash.
The non-alcoholic steatohepatitis treatment market is anticipated to experience significant expansion in the upcoming years, projected to reach $18.97 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 39.7%. This considerable growth during the forecast period is attributed to several factors, including advancements in precision medicine, the development of novel NASH drugs, the increasing adoption of digital health monitoring tools, government initiatives aimed at preventing liver disease, and a surge in investment dedicated to liver disease research. Furthermore, prominent trends expected over the forecast period involve personalized lifestyle and diet management, innovations in non-invasive diagnostics, the implementation of fatty liver disease awareness programs, the rise of home-based liver health monitoring, and the ongoing development of novel pharmacological agents.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Which Strategic Drivers Are Supporting The Non-Alcoholic Steatohepatitis Treatment Market Development?
The escalating occurrence of insulin resistance is set to drive the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when muscle, fat, and liver cells inadequately respond to insulin, impeding glucose absorption from the blood and resulting in elevated blood sugar levels. This condition is associated with poor lifestyle choices, excessive sugar intake, and genetic predispositions. The prevalence of insulin resistance has expanded considerably due to the rise in diabetes and other liver-related problems, both of which are addressed by non-alcoholic steatohepatitis treatment. For instance, in July 2025, PubMed, a US-based free biomedical literature database maintained by the U.S. National Library of Medicine, reported significant increases in prevalence rates: general obesity from 34.9% to 41.4%, abdominal obesity from 62.5% to 67.0%, severe obesity from 5.2% to 11.5%, and insulin resistance from 22.5% to 30.2%, respectively. Thus, the increasing prevalence of insulin resistance, stemming from numerous liver and diabetes diseases, will act as a key driver for the non-alcoholic steatohepatitis treatment market.
How Is The Non-Alcoholic Steatohepatitis Treatment Market Examined Through Segment Analysis?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor Monotherapy, Elafibranor Combination Therapy
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Immediate-Release Obeticholic Acid, Extended-Release Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Which Trends Are Influencing The Direction Of The Non-Alcoholic Steatohepatitis Treatment Market?
Leading companies in the non-alcoholic steatohepatitis treatment market are creating innovative products, such as endogenous hormones, to cater to larger customer bases, boost sales, and increase revenue. Endogenous hormones are naturally occurring substances produced internally by various glands, tissues, or organs, and they play vital roles in regulating physiological processes. For instance, in September 2023, 89bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for Pegozafermin for individuals diagnosed with nonalcoholic steatohepatitis (NASH). Pegozafermin is notable as a distinctive product due to its engineered glycoPEGylated analog of fibroblast growth factor 21. This specifically designed formulation is under development for addressing non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). What makes Pegozafermin unique is its utilization of a specialized glycoPEGylated technology, ensuring an extended half-life while preserving its potency. This innovative approach enhances the product’s effectiveness in modulating key factors related to lipid metabolism, NASH, and hypertriglyceridemia, including triglyceride reduction, glycemic control, steatosis, inflammation, and fibrosis.
Which Companies Are Engaged In The Non-Alcoholic Steatohepatitis Treatment Market Environment?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Access The Complete Non-Alcoholic Steatohepatitis Treatment Market Report:
Which Geographic Region Represents The Largest Non-Alcoholic Steatohepatitis Treatment Market Share?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2025. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Non-Alcoholic Steatohepatitis Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Treatment Market 2026, By The Business Research Company
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model